Search
Rivastigmine Action Pathway (new)
smpdb.ca/view/SMP0126688Drug actionRivastigmine is a cholinesterase inhibitor used in the treatment of symptoms of dementia in Alzheimer's and Parkinson's.
Rivastigmine Predicted Metabolism Pathway
smpdb.ca/view/SMP0174555MetabolicMetabolites of Rivastigmine are predicted with biotransformer.
Sialuria or French Type Sialuria
smpdb.ca/view/SMP0000216DiseaseSialuria is caused by mutation in the gene encoding uridinediphosphate-N-acetylglucosamine 2-epimerase (UDP-GlcNAc 2-epimerase, which causes an excessive synthesis of sialic acid (N-acetylneuraminic acid, NeuAc). This causes accumulation...
Sialuria or French Type Sialuria
smpdb.ca/view/SMP0000217DiseaseSialuria is caused by mutation in the gene encoding uridinediphosphate-N-acetylglucosamine 2-epimerase (UDP-GlcNAc 2-epimerase, which causes an excessive synthesis of sialic acid (N-acetylneuraminic acid, NeuAc). This causes accumulation...
Sialuria or French Type Sialuria
smpdb.ca/view/SMP0125712DiseaseSialuria is caused by mutation in the gene encoding uridinediphosphate-N-acetylglucosamine 2-epimerase (UDP-GlcNAc 2-epimerase, which causes an excessive synthesis of sialic acid (N-acetylneuraminic acid, NeuAc). This causes accumulation...